Graticule Asia Macro Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Graticule Asia Macro Advisors’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-10,300	Closed	-$427K	–	191
2015 Q4	$427K	Sell	10,300 -97,370	-90%	-$3.26M	0.07%	160
2015 Q3	$1.66M	Buy	+107,670	New	+$2.31M	0.19%	55

Other funds holding FPRX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Graticule Asia Macro Advisors's FPRX Position: Q1 2016 in Review

Graticule Asia Macro Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2016, closing a stake of 10,300 shares — an estimated $427K sold.

Graticule Asia Macro Advisors first reported a position in FPRX in Q3 2015 and held it in 2 quarters. The position peaked at $1.66M in Q3 2015. 140 funds tracked by Wall St. Rank hold FPRX as of Q1 2016.

Graticule Asia Macro Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
Graticule Asia Macro Advisors sold 10,300 Five Prime Therapeutics, Inc. shares in Q1 2016, an estimated $427K.
Graticule Asia Macro Advisors first reported a position in Five Prime Therapeutics, Inc. in Q3 2015 and held it in 2 quarters.
Graticule Asia Macro Advisors's Five Prime Therapeutics, Inc. position peaked at $1.66M in Q3 2015.
140 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2016.

Based on Graticule Asia Macro Advisors's 13F filing for Q1 2016, filed 13 May 2016.